Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6706654 | 0.85 | KCNH2 (0.60) | KCNH2 | |
| SCHEMBL6479266 | 0.83 | KCNH2 (0.53) | MAPTKCNH2MEN1KMT2A | |
| SCHEMBL6481165 | 0.82 | MAPT (0.53) | MAPTKCNH2MEN1KMT2A | |
| SCHEMBL6481474 | 0.81 | KCNH2 (0.53) | MAPTKCNH2MEN1KMT2A | |
| SCHEMBL6668589 | 0.80 | MAPT (0.61) | MAPTMEN1KMT2A | |
| SCHEMBL6632634 | 0.79 | KCNH2 (0.49) | KCNH2 | |
| SCHEMBL6286401 | 0.78 | MAPT (0.54) | MAPTKCNH2MEN1KMT2A | |
| SCHEMBL6707876 | 0.78 | MEN1 (0.51) | MEN1KMT2A | |
| SCHEMBL6707971 | 0.78 | KCNH2 (0.48) | KCNH2 | |
| SCHEMBL6286417 | 0.77 | MAPT (0.49) | MAPTKCNH2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6861438-B2 | Antiviral agents | PFIZER (US) | 2005-03-01 | — | — | US | claimed |
| US-20040138449-A1 | Antiviral agents | PHARMACIA & UPJOHN COMPANY | 2004-07-15 | — | — | US | claimed |
| US-6861438-B2 | Antiviral agents | PFIZER (US) | 2005-03-01 | — | — | US | disclosed |
| EP-1467999-A1 | OXOTHIENO[3,2-B]PYRIDINECARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2004-10-20 | — | — | EP | disclosed |
| US-20040138449-A1 | Antiviral agents | PHARMACIA & UPJOHN COMPANY | 2004-07-15 | — | — | US | disclosed |
| WO-2003059912-A1 | OXOTHIENO (3, 2-B) PYRIDINECARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2003-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138449-A1 | Antiviral agents | IRF3, IFNAR1, EIF2AK2 | MAPT 3921/4885KCNH2 766/4885MEN1 1116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.